Dimerix Ltd has released a press release.
ARDS in COVID-19 Patients Protocol Published
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Positive Additional Data to Support DMX-200 Development
- Receipt of R&D Tax Incentive
- DMX-700 Data Demonstrates Effect on Key COPD Receptors
- Positive Top-Line Results in DKD Phase 2 Clinical Study
- Dimerix Awarded $1 Million MRFF Funding
Later from Dimerix
- Second Study to Include DMX-200 in COVID-19 Patients
- Dimerix Plans for Next Study in Diabetic Kidney Disease
- Appendix 4D and Interim Financial Report
- CLARITY 2.0 Study Progresses In Patients With COVID-19
- DMX-200 Competitive Position Further Enhanced
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix